SRR615020
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.470
- INFLAMMATORY_RESPONSE+0.448
- IL6_JAK_STAT3_SIGNALING+0.418
- TNFA_SIGNALING_VIA_NFKB+0.380
- ANGIOGENESIS+0.375
- MYOGENESIS+0.336
- IL2_STAT5_SIGNALING+0.322
- INTERFERON_GAMMA_RESPONSE+0.316
- KRAS_SIGNALING_UP+0.315
- INTERFERON_ALPHA_RESPONSE+0.281
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.639
- DNA_REPAIR-0.504
- HEDGEHOG_SIGNALING-0.437
- MYC_TARGETS_V2-0.427
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.408
- UNFOLDED_PROTEIN_RESPONSE-0.390
- MYC_TARGETS_V1-0.380
- NOTCH_SIGNALING-0.370
- ADIPOGENESIS-0.341
- GLYCOLYSIS-0.285
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR602131 | GTEX | — | 0.961 |
| 2 | SRR1120755 | GTEX | — | 0.955 |
| 3 | SRR608598 | GTEX | — | 0.950 |
| 4 | SRR1335047 | GTEX | — | 0.949 |
| 5 | SRR1474795 | GTEX | — | 0.945 |
| 6 | SRR1368964 | GTEX | — | 0.944 |
| 7 | SRR1330546 | GTEX | — | 0.943 |
| 8 | SRR1310623 | GTEX | — | 0.932 |
| 9 | SRR1370173 | GTEX | — | 0.931 |
| 10 | SRR1369219 | GTEX | — | 0.929 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.448 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.418 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.375 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.336 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.322 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.316 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.315 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.281 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.266 | Inavolisib | — uncovered |
| COAGULATION | 0.262 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.231 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.208 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.189 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.165 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.105 | Cobimetinib | — uncovered |
| P53_PATHWAY | 0.055 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.054 | Inavolisib | — uncovered |